These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27900609)

  • 1. Dry Age-Related Macular Degeneration Pharmacology.
    Wright CB; Ambati J
    Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell based therapies for age-related macular degeneration: The promises and the challenges.
    Nazari H; Zhang L; Zhu D; Chader GJ; Falabella P; Stefanini F; Rowland T; Clegg DO; Kashani AH; Hinton DR; Humayun MS
    Prog Retin Eye Res; 2015 Sep; 48():1-39. PubMed ID: 26113213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for atrophic macular degeneration.
    Meleth AD; Wong WT; Chew EY
    Curr Opin Ophthalmol; 2011 May; 22(3):190-3. PubMed ID: 21427574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy.
    Cahill MT; Mruthyunjaya P; Bowes Rickman C; Toth CA
    Arch Ophthalmol; 2005 Jul; 123(7):935-8. PubMed ID: 16009834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group.
    ; Domalpally A; Clemons TE; Danis RP; Sadda SR; Cukras CA; Toth CA; Friberg TR; Chew EY
    Ophthalmology; 2017 Apr; 124(4):479-487. PubMed ID: 28089680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.
    Li H; Chintalapudi SR; Jablonski MM
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1103-1114. PubMed ID: 28816076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on geographic atrophy in age-related macular degeneration.
    Biarnés M; Monés J; Alonso J; Arias L
    Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell therapies for age-related macular degeneration: the past, present, and future.
    Dang Y; Zhang C; Zhu Y
    Clin Interv Aging; 2015; 10():255-64. PubMed ID: 25609937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of age-related macular degeneration and therapeutic opportunities.
    van Lookeren Campagne M; LeCouter J; Yaspan BL; Ye W
    J Pathol; 2014 Jan; 232(2):151-64. PubMed ID: 24105633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot Topics in Dry AMD.
    Narayanan R; Kuppermann BD
    Curr Pharm Des; 2017; 23(4):542-546. PubMed ID: 28003009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment.
    Vavvas DG; Daniels AB; Kapsala ZG; Goldfarb JW; Ganotakis E; Loewenstein JI; Young LH; Gragoudas ES; Eliott D; Kim IK; Tsilimbaris MK; Miller JW
    EBioMedicine; 2016 Mar; 5():198-203. PubMed ID: 27077128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of age-related macular degeneration: an update for pharmacists.
    Marshall LL; Roach JM
    Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration.
    Jang KH; Do YJ; Son D; Son E; Choi JS; Kim E
    Cell Death Dis; 2017 Jan; 8(1):e2526. PubMed ID: 28055012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical Coherence Tomography Features Preceding the Onset of Advanced Age-Related Macular Degeneration.
    Ferrara D; Silver RE; Louzada RN; Novais EA; Collins GK; Seddon JM
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3519-3529. PubMed ID: 28715590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.
    Danis RP; Lavine JA; Domalpally A
    Clin Ophthalmol; 2015; 9():2159-74. PubMed ID: 26640366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Age-Related Macular Degeneration Therapies.
    Fabre M; Mateo L; Lamaa D; Baillif S; Pagès G; Demange L; Ronco C; Benhida R
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical coherence tomography-based measurement of drusen load predicts development of advanced age-related macular degeneration.
    Nathoo NA; Or C; Young M; Chui L; Fallah N; Kirker AW; Albiani DA; Merkur AB; Forooghian F
    Am J Ophthalmol; 2014 Oct; 158(4):757-761.e1. PubMed ID: 24983793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection for Age-Related Macular Degeneration.
    Lin JB; Murakami Y; Miller JW; Vavvas DG
    Ophthalmol Sci; 2022 Dec; 2(4):100192. PubMed ID: 36570623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.